Among Scalp Non-Responder Patients with Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment with Baricitinib Resulted in Meaningful Scalp Responses for Patients with Severe Alopecia Areata

In a study involving 78 patients with severe alopecia areata (AA) treated with baricitinib 4mg, researchers found that continued treatment beyond the first year led to significant scalp hair regrowth. Initially, these patients showed eyebrow and/or eyelash regrowth but no scalp response. By Week-104, 39% of the patients achieved a Severity of Alopecia Tool (SALT) score of ≤20, indicating meaningful scalp hair regrowth, which persisted through Week-152. The mean percent improvement in SALT score increased from 35% at Week-52 to 55% at Week-152. This suggests that ongoing baricitinib treatment can result in substantial scalp hair regrowth in patients with severe AA, particularly those with alopecia universalis.